Erratum: First Global Approval (Drugs (2015) 75 (2035-2043) DOI: 10.1007/s40265-015-0494-7);Cariprazine: First Global Approval

Drugs

Volumn 75, Issue 17, 2015, Pages 2035-2043

  McCormack, Paul L ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CARIPRAZINE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

AKATHISIA; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BIPOLAR I DISORDER; CHEMICAL STRUCTURE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; HAMILTON DEPRESSION RATING SCALE; HUMAN; HYPERTRANSAMINASEMIA; INSOMNIA; MANIA; MAXIMUM PLASMA CONCENTRATION; MIXED MANIA AND DEPRESSION; NAUSEA; NONHUMAN; PARKINSONISM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SHEEHAN DISABILITY SCALE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; UNITED STATES; VOMITING; YOUNG MANIA RATING SCALE; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; INTERNATIONAL COOPERATION; PATENT;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DRUG APPROVAL; HUMANS; INTERNATIONALITY; PATENTS AS TOPIC; PIPERAZINES; SCHIZOPHRENIA;

EID: 84946921406     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-016-0547-6     Document Type: Erratum

References (31)

1. 2 receptors for antipsychotic activity. Handb Exp Pharmacol. 2012;212:27-52.
2. Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367-73.
3. 3 receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol. 2012;213:167-210.
4. 2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(5):529-39.
5. 2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(5):515-28.
6. US FDA. FDA approves new drug to treat schizophrenia and bipolar disorder [media release]. 17 Sep 2015. http://www.fda.gov.
7. US FDA. Vraylar™ (cariprazine): US prescribing information. 2015. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed 29 Sep 2015.
8. Forest Laboratories Inc. Gedeon Richter and Forest Laboratories announce collaboration agreement on atypical antipsychotic for schizophrenia, bipolar mania and other psychiatric disorders [media release]. 22 Nov 2004. http://www.frx.com.
9. Gedeon Richter Ltd. License and collaboration agreement between Gedeon Richter Ltd. and Mitsubishi Pharma Corporation on development of an atypical antipsychotic [media release]. 11 May 2006. http://www.richer.hu.
10. 2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328-40.
11. 1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl). 2011;218(3):579-87.
12. 3 -receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2013;226(1):91-100.
13. 2 receptor β-arrestin interactions. Pharmacol Res Perspect. 2015;3(1):e00073.
14. 3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59(6):925-35.
15. Slifstein M, Abi-Dargham A, D'Souza DC, et al. Cariprazine demonstrates high dopamine D3 and D2 receptor occupancy in patients with schizophrenia: a clinical PET study with [11C]-(+)-PHNO [abstract no. W128]. Neuropsychopharmacology. 2013;38(Suppl 2):S520-1.
16. Lee Y, Periclou A, Kapás M, et al. Pharmacokinetics of cariprazine in healthy subjects and patients with impaired hepatic function [abstract no. PI-101]. Clin Pharmacol Ther. 2014;95(Suppl 1):S51.
17. Pásztor Mészáros G, Kapás M, Borsos M, et al. Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects [abstract no. P.3.c.047]. Eur Neuropsychopharmacol. 2007;17(Suppl 4):S451-2.
18. Nakamura T, Kubota T, Imada M. Pharmacokinetic characterization of cariprazine and its metabolites during 12 weeks of dosing and 12 weeks of follow-up [abstract no. 97]. In: 168th annual meeting of the American Psychiatric Association; 2015.
19. Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2-3):450-7.
20. Lieberman JA, Cutler AJ, Wan S, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo-and active-controlled trial [abstract no. P.3.d.033]. Eur Neuropsychopharmacol. 2013;23(Suppl 2):S477-8.
21. Cutler AJ, Durgam S, Lu K, et al. Trajectory of cariprazine treatment effects across schizophrenia symptoms: post hoc analysis of a randomized, double-blind, placebo and active-controlled trial [abstract]. Schizophr Bull. 2015;41(Suppl 1):S308.
22. Durgam S, Earley W, Li R, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2015;25(Suppl 2):S512-3.
23. Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17(1):63-75.
24. Calabrese JR, Keck PE, Starace A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284-92.
25. Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double- blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296-302.
26. Debelle M, Németh G, Szalai E, et al. Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial [abstract no. P.3.d.053]. Eur Neuropsychopharmacol. 2015;25(Suppl 2):S510.
27. Earley W, Mergel V, Durgam S, et al. Cariprazine as adjunctive therapy in major depressive disorder: a double-blind, placebo-controlled study [abstract no. LP-02-009]. In: 29th International Congress of Collegium Internationale Neuro-Psychopharmacologicum; 2014.
28. Calabrese JR, Durgam S, Lipschitz A, et al. Cariprazine monotherapy for the treatment of bipolar I depression: results of an 8-week, double-blind, placebo-controlled study [abstract no. T69]. Neuropsychopharmacology. 2014;39(S1):S335-6.
29. Durgam S, Lipschitz A, Guo H, et al. A double-blind, placebo-controlled study of cariprazine monotherapy for the treatment of bipolar I depression [abstract]. Bipolar Disord. 2015;17(Suppl 1):90-1.
30. Durgam S, Cutler AJ, Wang Y, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia [abstract no. M227 plus poster]. Schizophr Res. 2014;153(Suppl 1):S272.
31. Ketter TA, Sachs GS, Lu K, et al. Long-term safety and tolerability of open-label cariprazine in patients with bipolar I disorder [abstract no. P.2.d.024]. Eur Neuropsychopharmacol. 2013;23(Suppl 2):S377.